WWL113|cas:947669-86-5|西域试剂

WWL113,99.08%

产品编号：Bellancom-110148| CAS NO：947669-86-5| 分子式：C₂₉H₂₆N₂O₄| 分子量：466.53

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-110148	￥1200.00	杭州北京（现货）
Bellancom-110148	￥1800.00	杭州北京（现货）
Bellancom-110148	￥3600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

WWL113

产品介绍

WWL113 是具有口服活性的、选择性的 Ces3 和 Ces1f 的抑制剂，其对 Ces3 和 Ces1f 的 IC₅₀ 值分别为 120 nM 和 100 nM。WWL113 对 60-kDa丝氨酸水解酶(或水解酶)有极好的选择性。

生物活性

WWL113 is a selective and orally active Ces3 and Ces1f inhibitor, with IC₅₀ values of 120 nM and 100 nM for Ces3 and Ces1f, respectively. WWL113 appears to show excellent selectivity for the 60-kDa serine hydrolase (or hydrolases).

体外研究

Ces3 and Ces1f are endoplasmic reticulum glycoproteins that have been previously associated with adipocyte lipolysis. WWL113 inhibits mouse recombinant Ces1, Ces1c, and ABHD6 at 10 μM.
WWL113 (1 μM) significantly increases UCP1 protein expression in brown adipocytes.
WWL113 has a partial, statistically significant inhibitory effect on blocking the buildup of PGE2.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

WWL113 (30 mg/kg, orally once a day) results in major improvement of multiple features of metabolic syndrome and ameliorated obesity-diabetes in mice with lowered levels of nonesterified free fatty acids (NEFAs), triglycerides (TGs), total cholesterol and fasted glucose as well as enhanced glucose tolerance.
WWL113 ameliorates obesity-diabetes in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eight-week-old db/db mice (n = 10 per group).
Dosage:	30 mg/kg.
Administration:	Orally once a day for 3 weeks.
Result:	Corrected multiple features of metabolic syndrome in db/db mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eight-week-old db/db mice (n = 10 per group).
Dosage:	30 mg/kg.
Administration:	Orally once a day for 3 weeks.
Result:	Corrected multiple features of metabolic syndrome in db/db mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 20.83 mg/mL (44.65 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1435 mL	10.7174 mL	21.4348 mL
5 mM	0.4287 mL	2.1435 mL	4.2870 mL
10 mM	0.2143 mL	1.0717 mL	2.1435 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.46 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.46 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。